Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, Virginia. Center for Cell Signaling, University of Virginia, Charlottesville, Virginia.
Cancer Discov. 2014 Oct;4(10):1123-5. doi: 10.1158/2159-8290.CD-14-0861.
A subset of glioblastomas (GBM) has high levels of TGFβ signaling, and anti-TGFβ therapies are being pursued as treatments for GBM. The work presented here identifies CREB1 as a potential biomarker for TGFβ-dependent GBM. CREB1 integrates signaling from TGFβ and the PI3K pathway and nucleates a self-sustaining signaling loop that maintains TGFβ2 expression in GBM with high CREB1 levels.
一部分胶质母细胞瘤（GBM）具有高水平的 TGFβ 信号，因此正在寻求抗 TGFβ 疗法作为 GBM 的治疗方法。这里介绍的工作确定 CREB1 是 TGFβ 依赖性 GBM 的潜在生物标志物。CREB1 整合 TGFβ 和 PI3K 途径的信号，并形成一个自我维持的信号环，在 CREB1 水平高的 GBM 中维持 TGFβ2 的表达。
